AU2022422997A1 - Crystalline form of glp-1 receptor agonist and preparation method therefor - Google Patents
Crystalline form of glp-1 receptor agonist and preparation method therefor Download PDFInfo
- Publication number
- AU2022422997A1 AU2022422997A1 AU2022422997A AU2022422997A AU2022422997A1 AU 2022422997 A1 AU2022422997 A1 AU 2022422997A1 AU 2022422997 A AU2022422997 A AU 2022422997A AU 2022422997 A AU2022422997 A AU 2022422997A AU 2022422997 A1 AU2022422997 A1 AU 2022422997A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- crystal form
- methyl
- characteristic peaks
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111586541.3 | 2021-12-23 | ||
| CN202111586541 | 2021-12-23 | ||
| PCT/CN2022/141407 WO2023116879A1 (zh) | 2021-12-23 | 2022-12-23 | 一种glp-1受体激动剂的结晶形式及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022422997A1 true AU2022422997A1 (en) | 2024-07-11 |
Family
ID=86901327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022422997A Pending AU2022422997A1 (en) | 2021-12-23 | 2022-12-23 | Crystalline form of glp-1 receptor agonist and preparation method therefor |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| EP4130005A4 (en) * | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
| PT4157832T (pt) * | 2020-05-27 | 2024-07-30 | Qilu Regor Therapeutics Inc | Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos |
| JP7812052B2 (ja) * | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
-
2022
- 2022-12-23 KR KR1020247024148A patent/KR20240125004A/ko active Pending
- 2022-12-23 PT PT229101902T patent/PT4455140T/pt unknown
- 2022-12-23 US US18/722,345 patent/US20250049778A1/en active Pending
- 2022-12-23 MX MX2024007907A patent/MX2024007907A/es unknown
- 2022-12-23 WO PCT/CN2022/141407 patent/WO2023116879A1/zh not_active Ceased
- 2022-12-23 EP EP22910190.2A patent/EP4455140B1/en active Active
- 2022-12-23 AU AU2022422997A patent/AU2022422997A1/en active Pending
- 2022-12-23 ES ES22910190T patent/ES3070919T3/es active Active
- 2022-12-23 DK DK22910190.2T patent/DK4455140T3/da active
- 2022-12-23 EP EP26159633.2A patent/EP4725484A3/en active Pending
- 2022-12-23 FI FIEP22910190.2T patent/FI4455140T3/fi active
- 2022-12-23 TW TW111149828A patent/TW202328115A/zh unknown
- 2022-12-23 PL PL22910190.2T patent/PL4455140T3/pl unknown
- 2022-12-23 CN CN202280084770.1A patent/CN118401518A/zh active Pending
- 2022-12-23 CA CA3241677A patent/CA3241677A1/en active Pending
- 2022-12-23 JP JP2024537982A patent/JP2024547112A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT4455140T (pt) | 2026-05-22 |
| CA3241677A1 (en) | 2023-06-29 |
| DK4455140T3 (da) | 2026-05-26 |
| EP4455140A4 (en) | 2025-04-09 |
| PL4455140T3 (pl) | 2026-06-29 |
| EP4455140A1 (en) | 2024-10-30 |
| FI4455140T3 (fi) | 2026-05-28 |
| US20250049778A1 (en) | 2025-02-13 |
| EP4725484A2 (en) | 2026-04-15 |
| MX2024007907A (es) | 2024-07-12 |
| CN118401518A (zh) | 2024-07-26 |
| JP2024547112A (ja) | 2024-12-26 |
| TW202328115A (zh) | 2023-07-16 |
| EP4455140B1 (en) | 2026-04-01 |
| KR20240125004A (ko) | 2024-08-19 |
| WO2023116879A1 (zh) | 2023-06-29 |
| EP4725484A3 (en) | 2026-06-10 |
| ES3070919T3 (en) | 2026-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4455141B1 (en) | Pharmaceutically acceptable salt and crystalline form of a glp-1 receptor agonist for the treatment of diabetes | |
| EP4455140B1 (en) | Crystalline forms of a glp-1 receptor agonist and preparation methods therefor | |
| EP4332102A1 (en) | Isoquinolone compound and use thereof | |
| CN120359210A (zh) | Cyp11b2抑制剂化合物、药物组合物及其应用 | |
| EP4538277A1 (en) | Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt | |
| US20250353839A1 (en) | Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof | |
| US20240374581A1 (en) | Salt types of tricyclic tetrahydro isoquinoline derivative | |
| JP4605218B2 (ja) | キヌクリジン誘導体の新規な塩 | |
| WO2008062047A1 (en) | Process for preparing a crystalline form of candesartan cilexetil | |
| TW202519227A (zh) | 稠環衍生物、其製備方法及其在醫藥上的應用 | |
| WO2024193455A1 (zh) | 一种1,4-二氢-1,6-萘啶酰胺化合物的可药用盐、晶型及其制备方法 | |
| TWI914461B (zh) | 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法 | |
| CN112500353B (zh) | 一种左西孟旦的前药化合物、制备方法及其应用 | |
| CN114644616B (zh) | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 | |
| TW202333694A (zh) | 稠環衍生物的晶型、其製備方法及其應用 | |
| CN120535504A (zh) | 一种p38α-MK2抑制剂的晶型及其制备方法和应用 | |
| KR20250174948A (ko) | 질소 함유 테트라시클릭 화합물의 결정 형태 및 이의 제조 방법 | |
| WO2024159211A1 (en) | Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement | |
| CN118556054A (zh) | 一种p2x3受体拮抗剂的结晶形式及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Free format text: FORMER APPLICANT(S): JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.; SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |